OPCHNasdaqServices-Home Health Care ServicesFiscal year ends December 31
Option Care Health, Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Jul 29, 2026
$31.21+0.01 (+0.03%)
Close on Oct 19, 2026
- Market cap
- $4.94B
- P/E (TTM)
- 24.2
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
19.3%−3.2 pts over 5 years
Operating margin
6.0%+2.3 pts over 5 years
Net margin
3.7%+3.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +13.0% | +12.7% | +13.3% | – | |
| Gross profit | +7.4% | +7.9% | +9.8% | +15.4% | |
| Operating income | +5.0% | +12.0% | +25.0% | – | |
| Net income | -2.0% | +11.3% | – | – | |
| EPS, diluted | +3.3% | +15.2% | – | – | |
| Free cash flow | -24.5% | -2.2% | +16.7% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -16.5% | -0.8% | 15.2% | |
| Return on assets | -7.5% | -0.3% | 6.0% | |
| Current ratio | 1.33 | 1.51 | 1.53 | |
| Debt to equity | 0.75 | 1.11 | 0.88 | |
| Net debt to EBITDA | 36.89× | 5.63× | 2.29× | |
| Interest coverage | – | 1.0× | 6.2× | |
| Inventory turnover | 17.0× | 17.1× | 10.6× | |
| Capex to revenue | – | 0.9% | 0.7% | |
| Diluted shares | 105M | 181M | 163M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Option Care Health generated $1.43B from operations and spent $992.71M on capital expenditure, dividends and share buybacks. 18% of that went back into the business.
Generated
$1.43B
Used
$992.71M
Capital expenditure$179.77M18%Dividends$00%Share buybacks$812.94M82%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin3.7%
×Asset turnover1.64×
×Equity multiplier2.52×
=Return on equity, FY202515.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 3.7% | 1.64× | 2.52× | 15.2% |
| FY2024 | 4.2% | 1.51× | 2.35× | 15.0% |
| FY2023 | 6.2% | 1.36× | 2.25× | 19.0% |
| FY2022 | 3.8% | 1.34× | 2.30× | 11.8% |
| FY2021 | 4.1% | 1.26× | 2.48× | 12.8% |
| FY2020 | -0.3% | 1.16× | 2.72× | -0.8% |
| FY2019 | -3.3% | 1.15× | 2.66× | -10.1% |
| FY2018 | -0.3% | 1.91× | 1.68× | -1.0% |
| FY2017 | 0.2% | 3.03× | 1.00× | 0.6% |
| FY2016 | -4.6% | 1.65× | 2.19× | -16.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$207.59M
- Cash generatingOperating cash flow above zero$258.45M
- Return on assets improvedROA up on the prior year6.6% → 6.1%
- Earnings backed by cashOperating cash flow above net income$258.45M vs $207.59M
- Less leverageLong-term debt to assets fell32.3% → 33.4%
- Better liquidityCurrent ratio rose1.70 → 1.53
- No dilutionShare count did not rise173M → 163M
- Gross margin improvedGross margin up on the prior year20.27% → 19.26%
- More efficientAsset turnover rose1.55 → 1.65